Biogen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. 

CEO
Christopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees
7,605
Employees7,605
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1978
Founded1978
Employees
7,605
Employees7,605

BIIB Key Statistics

Market cap
19.44B
Market cap19.44B
Price-Earnings ratio
13.05
Price-Earnings ratio13.05
Dividend yield
Dividend yield
Average volume
1.35M
Average volume1.35M
High today
$136.62
High today$136.62
Low today
$132.04
Low today$132.04
Open price
$136.36
Open price$136.36
Volume
1.54M
Volume1.54M
52 Week high
$206.70
52 Week high$206.70
52 Week low
$110.04
52 Week low$110.04

BIIB News

TipRanks 1d
UK’s MHRA approves Biogen’s Zurzuvae for postnatal depression

The Medicines and Healthcare products Regulatory Agency said it has approved Zurzuvae to treat moderate or severe postnatal depression in adults following child...

TipRanks 3d
Biogen, Stoke Therapeutics present data from studies of zorevunersen

Biogen Inc. (BIIB) and Stoke Therapeutics (STOK) announced presentations of new clinical data from studies of zorevunersen at the 36th International Epilepsy Co...

TipRanks 3d
Eisai and Biogen launch Leqembi in Austria, Germany

Eisai (ESAIY) and Biogen (BIIB) announced that the anti-amyloid beta monoclonal antibody Leqembi has been launched in Austria on August 25 and will be launched...

Analyst ratings

49%

of 35 ratings
Buy
48.6%
Hold
48.6%
Sell
2.9%

More BIIB News

Simply Wall St 5d
Biogen: Reassessing Valuation After Recent Share Price Recovery

If you have been tracking Biogen (BIIB) lately, the company’s shares have quietly gained 6% in the past month, recapturing some ground after a tough stretch. Wh...

Biogen: Reassessing Valuation After Recent Share Price Recovery
TipRanks 6d
Biogen’s Innovative Study on Litifilimab Delivery: Market Implications and Study Insights

Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Prem...

TipRanks 6d
Biogen’s Phase 3 Study on Felzartamab: A Potential Game-Changer for IgA Nephropathy

Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Prem...

TipRanks 6d
Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment?

Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Prem...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.